1.Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis.
Gaeun KIM ; Young Woo EOM ; Soon Koo BAIK ; Yeonghee SHIN ; Yoo Li LIM ; Moon Young KIM ; Sang Ok KWON ; Sei Jin CHANG
Journal of Korean Medical Science 2015;30(10):1405-1415
Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.
Cell Differentiation/physiology
;
Cell- and Tissue-Based Therapy/adverse effects/*methods
;
Hepatocytes/cytology
;
Humans
;
Liver/physiopathology/surgery
;
Liver Diseases/*therapy
;
Liver Function Tests
;
Mesenchymal Stem Cell Transplantation/adverse effects/*methods
;
Mesenchymal Stromal Cells/*cytology
2.Biomaterials as carrier, barrier and reactor for cell-based regenerative medicine.
Chunxiao QI ; Xiaojun YAN ; Chenyu HUANG ; Alexander MELERZANOV ; Yanan DU
Protein & Cell 2015;6(9):638-653
Cell therapy has achieved tremendous success in regenerative medicine in the past several decades. However, challenges such as cell loss, death and immune-rejection after transplantation still persist. Biomaterials have been designed as carriers to deliver cells to desirable region for local tissue regeneration; as barriers to protect transplanted cells from host immune attack; or as reactors to stimulate host cell recruitment, homing and differentiation. With the assistance of biomaterials, improvement in treatment efficiency has been demonstrated in numerous animal models of degenerative diseases compared with routine free cell-based therapy. Emerging clinical applications of biomaterial assisted cell therapies further highlight their great promise in regenerative therapy and even cure for complex diseases, which have been failed to realize by conventional therapeutic approaches.
Animals
;
Biocompatible Materials
;
chemistry
;
pharmacology
;
Bioreactors
;
Cell- and Tissue-Based Therapy
;
adverse effects
;
methods
;
Drug Carriers
;
chemistry
;
pharmacology
;
Humans
;
Regenerative Medicine
;
methods